Rapid Increase in Tobacco Consumption in Kazakhstan in 2023

Market by 2FIRSTS.ai
Feb.04.2024
Rapid Increase in Tobacco Consumption in Kazakhstan in 2023
Kazakhstan's tobacco market experiences a sharp increase in sales as smoking rates surge by 68.7% in 2023.

According to a report by Kazakhstan's business news website, inbusiness.kz, the sales volume of tobacco and tobacco products in the domestic market of Kazakhstan saw a significant increase from January to November 2023, with a year-on-year growth rate of 68.7%, reaching a staggering 29.4 billion units in sales value.

 

According to data from the Global Adult Tobacco Survey (GATS), the total number of tobacco users in Kazakhstan has remained around 2.8 million from 2014 to 2019. In recent years, tobacco consumption in the country has been relatively stable. However, by 2023, there is a projected sharp increase in the number of smokers in Kazakhstan, reaching 19.4% of the population, equivalent to approximately 3.9 million people. This represents an increase of 1 million compared to previous data, indicating a significant rise in smoking rates.

 

One possible reason for this phenomenon is the recent decision in Kazakhstan to ban e-cigarettes, including their import, production, and sale, with violators facing criminal liability. Currently, this decision is still awaiting review in the Senate and requires the signature of President Kasym-Jomart Tokayev.

 

According to a report on the website of energy monitoring agency Energyprom, e-cigarettes are being banned as they are seen as a "competitor" to traditional tobacco products. A comprehensive study by the Royal College of London University has found that compared to traditional tobacco, e-cigarettes are considered to be healthier, with the use of e-cigarettes being at least 95% safer than traditional tobacco. This is because e-cigarettes do not produce combustion byproducts, reducing the risk of cancer, respiratory, and cardiovascular diseases.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
China Tobacco Hubei Industrial Co., Ltd Tests New Gas Release Nicotine Pouch Technology, According to Patent Documents
China Tobacco Hubei Industrial Co., Ltd Tests New Gas Release Nicotine Pouch Technology, According to Patent Documents
China Tobacco Hubei Industrial Co., Ltd applies for patents on new nicotine pouch technology with gas release feature.
Mar.04 by 2FIRSTS.ai
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21